Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial

Table 4 Summary of findings compared to other prospective studies that administered intravenous iron and measured FGF23.

Study:	Current study		Hryszko, 2012 [14]	Takeda, 2011 [15]	Prats, 2013 [20]	Wolf, 2013 [13]		Schouten, 2009 [12]
Patient group	HD		HD	HD	CKD	Iron deficient women, no CKD		Medical outpatients, no CKD
Number of participants	20	22	12	27	47	25	30	8
Baseline ferritin (μg/L)	187 ± 130	211 ± 133	64.4 ± 32.7	31 ± 23	67.8 ± 61.7	4.4 ± 0.6	6.9 ± 1.7
Iron formulation	IS	FCM	Iron dextran	Saccharated ferric oxide	FCM	FCM	Iron dextran	Iron polymaltose
Iron dose regimen:	1 dose of 200 mg	1 dose of 200 mg	1 dose individualised, mean = 450 mg	9 doses of 40 mg after dialysis (total = 360 mg)	1 dose (15 mg/kg to a maximum of 1000 mg, mean = 972 mg)	1 dose (15 mg/kg to a maximum of 1000 mg, mean = 918 mg)	1 dose (15 mg/kg to a maximum1,000 mg, mean = 911 mg)	1 dose (mean = 918 mg, range 500–1600 mg)
FGF23 measures post-infusion:	2, 7, 21, 42 days	2, 7, 21, 42 days	Weeks 1 & 3	Weeks 1, 3 & 5	Week 3 & 12	Days 1, 7, 14, 28 & 35	Days 1, 7, 14, 28 & 35	Weekly for up to 7 weeks
iFGF23	−	↓	↑	↑		↑^a	−	↑↑
cFGF23	−	↑			↓	↓↓	↓↓
Ferritin	↑↑	↑↑	↑	↑	↑	↑↑^a	↑
Hepcidin	↑	↑↑^a				↑	↑↑^a
Phosphate	−	↓	−	−	↓	↓	−	↓

CKD chronic kidney disease, iFGF23 intact fibroblast growth factor 23, cFGF23 c-terminal fibroblast growth factor 23, HD haemodialysis patients, FCM ferric carboxymaltose, IS iron sucrose
Blank cells indicate that the analyte was not measured, ‘-’ indicates no change
^aSignificant between-group difference with time

ISSN: 1471-2369